Newron Pharma falls 4.4% as US FDA extends review for Parkinson's drug
Shares in Newron Pharmaceuticals (SIX: NWRN) dropped nearly 4.4%to 25.15 Swiss francs on the SIX Swiss Exchange after the company said the US regulator has extended the review time of its Parkinson's disease drug by three months.
The Italian drugmaker has filed a New Drug Application (NDA) for its Xadago (safinamide) with the US Food and Drug Administration. This extends the Prescription Drug User Fee Act (PDUFA) date to March 29, 2016.
The FDA has extended the review time for the Xadago to review the late submission of additional financial disclosure forms for two clinical studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze